Teva Pharmaceutical Industries Ltd.'s revenues declined 6% in the third quarter to $4.26bn, but the decline beat analyst expectations and costs were also lower than expected, signs of stabilization after years of revenue and earnings declines. Uncertainty over how much Teva could have to pay to settle ongoing opioid liability litigation in the US, however, continues to weigh on Teva's recovery.
The company released its third quarter financial results on 7 November and simultaneously announced the appointment of a new chief financial officer and the launch of the first biosimilar version of Roche's Rituxan (rituximab) in the US at the same time